| [1] |
Rao S V, O'donoghue M L, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the management of patients with acute coronary syndromes:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2025, 151(13):e771-e862. doi:10.1161/CIR.0000000000001309.
|
| [2] |
Byrne R A, Rossello X, Coughlan J J, et al. 2023 ESC Guidelines for the management of acute coronary syndromes[J]. Eur Heart J, 2023, 44(38):3720-3826. doi:10.1093/eurheartj/ehad191.
|
| [3] |
Frampton J, Ortengren A R, Zeitler E P. Arrhythmias after acute myocardial infarction[J]. Yale J Biol Med, 2023, 96(1):83-94. doi:10.59249/LSWK8578.
|
| [4] |
Del Buono M G, Moroni F, Montone R A, et al. Ischemic cardiomyopathy and heart failure after acute myocardial infarction[J]. Curr Cardiol Rep, 2022, 24(10):1505-1515. doi:10.1007/s11886-022-01766-6.
|
| [5] |
Bamarinejad F, Kermani-Alghoraishi M, Soleimani A, et al. Clinical,laboratory,and procedural predictors of slow flow/no reflow phenomenon after emergency percutaneous coronary interventions in ST-elevated myocardial infarction[J]. Egypt Heart J, 2024, 76(1):146. doi:10.1186/s43044-024-00577-0.
|
| [6] |
Doi S, Iwata H, Wada H, et al. A novel and simply calculated nutritional index serves as a useful prognostic indicator in patients with coronary artery disease[J]. Int J Cardiol, 2018, 262:92-98. doi:10.1016/j.ijcard.2018.02.039.
|
| [7] |
Pickell Z, Williams A M, Alam H B, et al. Histone deacetylase inhibitors:a novel strategy for neuroprotection and cardioprotection following ischemia/reperfusion injury[J]. J Am Heart Assoc, 2020, 9(11):e016349. doi:10.1161/JAHA.120.016349.
|
| [8] |
Ndrepepa G, Kastrati A. Coronary no-reflow after primary percutaneous coronary intervention-current knowledge on pathophysiology,diagnosis,clinical impact and therapy[J]. J Clin Med, 2023, 12(17):5592. doi:10.3390/jcm12175592.
|
| [9] |
Jneid H, Bozkurt B, Fonarow G C. The 2017 AHA/ACC performance and quality measures for patients with acute myocardial infarction[J]. JAMA Cardiol, 2018, 3(7):659-660. doi:10.1001/jamacardio.2018.0263.
|
| [10] |
Ibánez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J]. Rev Esp Cardiol(Engl Ed), 2017, 70(12):1082. doi:10.1016/j.rec.2017.11.010.
|
| [11] |
Kloner R A, Ganote C E, Jennings R B. The "no-reflow" phenomenon after temporary coronary occlusion in the dog[J]. J Clin Invest, 1974, 54(6):1496-1508. doi:10.1172/JCI107898.
|
| [12] |
Kaur G, Baghdasaryan P, Natarajan B, et al. Pathophysiology,diagnosis,and management of coronary no-reflow phenomenon[J]. Int J Angiol, 2021, 30(1):15-21. doi:10.1055/s-0041-1725979.
|
| [13] |
Omar M, Kang M G, Jung M K, et al. Association and prognostic implications of "No-Reflow Phenomenon" and hypercoagulability in patients with ST-segment elevation myocardial infarction[J]. JACC Asia, 2025, 5(11):1487-1501. doi:10.1016/j.jacasi.2025.07.015.
|
| [14] |
Bamarinejad A, Kermani-Alghoraishi M, Soleimani A, et al. Long-term outcome and prognostic value of angiographic slow/no-reflow phenomenon after emergency percutaneous coronary intervention for ST-elevation myocardial infarction[J]. Coron Artery Dis, 2024, 35(5):389-396. doi:10.1097/MCA.0000000000001362.
|
| [15] |
Refaat H, Tantawy A, Gamal A S, et al. Novel predictors and adverse long-term outcomes of no-reflow phenomenon in patients with acute ST elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Indian Heart J, 2021, 73(1):35-43. doi:10.1016/j.ihj.2020.12.008.
|
| [16] |
Ge L, Zhou X, Ji W J, et al. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow:therapeutic potential of DNase-based reperfusion strategy[J]. Am J Physiol Heart Circ Physiol, 2015, 308(5):H500-509. doi:10.1152/ajpheart.00381.2014.
|
| [17] |
Surendran A, Ismail U, Atefi N, et al. Lipidomic predictors of coronary no-reflow[J]. Metabolites, 2023, 13(1):79. doi:10.3390/metabo13010079.
|
| [18] |
Rezaee M, Kamrani F, Imannezhad M, et al. Beyond traditional metrics:evaluating the triglyceride-total cholesterol-body weight index(TCBI)in cardiovascular risk assessment[J]. BMC Cardiovasc Disord, 2025, 25(1):39. doi:10.1186/s12872-025-04500-6.
|
| [19] |
Aggarwal P, Rekwal L, Sinha S K, et al. Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction[J]. Ann Cardiol Angeiol(Paris), 2021, 70(3):136-142. doi:10.1016/j.ancard.2021.04.004.
|
| [20] |
Heper G, Korkmaz M E, Kilic A. Reperfusion arrhythmias:are they only a marker of epicardial reperfusion or continuing myocardial ischemia after acute myocardial infarction?[J]. Angiology, 2007, 58(6):663-670. doi:10.1177/0003319707308891.
|
| [21] |
Yu L, Chen J, Zhang J. Meta-analysis of the correlation between inflammatory response indices and no-reflow after PCI in patients with acute STEMI[J]. Am J Transl Res, 2024, 16(10):5168-5181. doi:10.62347/SUQT4991.
|
| [22] |
Fakhry H M, Eltelawy A, Othman K S, et al. Neutrophil-to-lymphocyte ratio and mean platelet volume in predicting coronary no-reflow in patients with st elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. The Egyptian Journal of Hospital Medicine, 2023, 91:4606-4613. doi:10.21608/ejhm.2023.297790.
|
| [23] |
Isshiki T, Kozuma K, Kyono H, et al. Initial clinical experience with distal embolic protection using "Filtrap",a novel filter device with a self-expandable spiral basket in patients undergoing percutaneous coronary intervention[J]. Cardiovasc Interv Ther, 2011, 26(1):12-17. doi:10.1007/s12928-010-0027-y.
|
| [24] |
Erlinge D, Tsimikas S, Maeng M, et al. Lipoprotein(a),cholesterol,triglyceride levels,and vulnerable coronary plaques:A PROSPECT II substudy[J]. J Am Coll Cardiol, 2025, 85(21):2011-2024. doi:10.1016/j.jacc.2025.04.013.
|
| [25] |
Jia Y P, Wang J M, Lyu J Q, et al. Triglyceride-rich lipoproteins cholesterol,10-years atherosclerotic cardiovascular disease risk,and risk of myocardial infarction and ischemic stroke[J]. J Lipid Res, 2024, 65(11):100653. doi:10.1016/j.jlr.2024.100653.
|
| [26] |
Jung E, Kong S Y, Ro Y S, et al. Serum cholesterol levels and risk of cardiovascular death:a systematic review and a dose-response meta-analysis of prospective cohort studies[J]. Int J Environ Res Public Health, 2022, 19(14):8272. doi:10.3390/ijerph19148272.
|